Monitor the upcoming conference call for more details on clinical trial timelines and the potential of VMS063. The slight delay in the DECLARATION study results to Q3 2026 should be factored into investment decisions.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 9 $1.78entry
- T+1 · 7mo ago −1.12%α −1.06% · $1.76
- T+5 · 7mo ago −3.93%α −7.12% · $1.71
- T+20 · 6mo ago −17.98%α −25.55% · $1.46
- T+60 · 4mo ago −53.15%α −63.93% · $0.8340
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd announced progress in its VYD2311 program for COVID-19 prevention and the discovery of a new measles monoclonal antibody candidate, VMS063. The company provided updates on clinical trial advancements and pipeline progress.
Key Facts
- Invivyd announced progress in its REVOLUTION program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention
- The DECLARATION Phase 3 study for VYD2311 has been upsized by approximately 500 additional subjects
- Top-line results for the DECLARATION study are now expected in Q3 2026, shifting from mid-year guidance
- The company has aligned with the FDA on an initial pediatric study plan for VYD2311
- Invivyd announced the discovery and advancement of VMS063, a novel measles monoclonal antibody candidate
- The company plans to host a conference call on April 9, 2026, at 8:30 AM ET
Financial Impact
No financial impact disclosed
Risk Factors
- Clinical trial delays could impact the timeline for regulatory submissions
- The measles antibody candidate VMS063 is still in early development stages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-148865 |
| Document: d147019dex992.htm | 0001193125-26-148865 |
| Document: d147019d8k.htm | 0001193125-26-148865 |
| Document: 0001193125-26-148865-index-headers.html | 0001193125-26-148865 |
| Document: 0001193125-26-148865-index.html | 0001193125-26-148865 |
| Document: 0001193125-26-148865.txt | 0001193125-26-148865 |
Track record
19 reports on IVVD
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers